Jefferies reiterates Buy on Eli Lilly stock, $1,300 target By Investing.com

Jefferies reiterated a Buy on Eli Lilly with a $1,300 price target (company market cap ~$803B, shares trading near $897), while Morgan Stanley, Leerink and BMO carry price targets of $1,313, $1,296 and $1,300 respectively. Oral Wegovy prescriptions were ~94,700 (IMS) and ~80,100 (Symphony) in week 11 (exceeding comparable 11th-week injectables of ~11,200 for Wegovy inj and ~57,700 for Zepbound pen), GLP-1 weekly volumes (week ending Mar 20) were ~730k Mounjaro, ~608k Zepbound, ~518k Ozempic and ~292k Wegovy inj with WoW changes: Wegovy inj +2%, Zepbound +0.03%, Mounjaro -3%, Ozempic -3%; Eli Lilly reported ~45% revenue growth over the past 12 months and its retatrutide Phase 3 TRANSCEND‑T2D‑1 met primary and all key secondary endpoints showing significant A1c reductions, supporting the bullish analyst stance.

Analysis

The immediate winner is the sponsor with scale in next‑generation GLP‑1 development and an entrenched commercial infrastructure; the less obvious beneficiaries are contract research and manufacturing suppliers who capture upstream margin as incumbents scale new indications and oral formulations. A second‑order effect: low‑cost generics launched in price‑sensitive markets accelerate payer negotiating leverage, compressing ASPs in developed markets through formulary pressure and parallel import dynamics within 12–24 months.

Key catalysts and timing: near‑term volatility will be driven by weekly prescription flows and quarterly calls (days–weeks), while durable share shifts play out over months as PBMs and payers rewrite access policies; patent litigation and bioequivalence pathways in emerging markets create event clusters at 6–18 months that can either lock in pricing or produce cliff‑like ASP declines. Regulatory/political risk (price caps, off‑label scrutiny) is a multi‑year tail that can convert revenue durability into permanent multiple compression.

Contrarian read: consensus is bifurcated — it prizes growth but underweights margin sensitivity to low‑price entrants and payer design. That makes the current risk/return asymmetric: clear upside if next‑gen efficacy unlocks label expansion and maintains premium pricing, but material downside if generics and PBM tactics erode realized prices; position sizing and time‑limited optionality therefore dominate optimal execution.

Key Decisions for Investors

• LLY — Express bullish, limited‑loss: Buy a 12–18 month call spread (buy 12m ATM call, sell 12m call ~+35% strike). Rationale: captures re‑rating on successful next‑gen readouts while capping premium; expect 2–4x payoff if market re‑prices growth. Max loss = premium paid; target time window 9–15 months to coincide with upcoming data/earnings.
• Pair trade — Long LLY / Short NVO, 6–12 months, equal dollar: Use equity or 9–12 month options to express class share migration. Rationale: asymmetric exposure to a sponsor with deeper pipeline and commercialization agility vs a higher‑exposure incumbent facing low‑cost competition. Risk: industry‑wide pricing action would hurt both; keep position size small (2–4% net fund risk).
• IQV — Tactical long (3–9 months): Buy stock or buy 9–12 month calls (small size). Rationale: CROs capture incremental per‑trial revenue and price renegotiation headroom as sponsors run more complex next‑gen programs. Look to take profits into earnings window; downside protected by diversified revenue base.
• Hedge/insurance — Buy healthcare sector downside protection for 6–12 months (XLV puts or S&P500 put spread) sized to cover 30–50% of LLY directional exposure. Rationale: protects against a swift payer‑driven repricing episode or regulatory shock that hits the whole GLP‑1 complex.
• Event short (opportunistic) — Short small cap or supplier names exposed to API price volatility for 3–6 months: size small, target ~1.5–2x return if supply chain CAPEX fails to resolve and input costs compress client margins. Trigger: public commentary of price concessions or contract losses to low‑cost entrants.